Ennio Lubrano
Overview
Explore the profile of Ennio Lubrano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
201
Citations
2220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ambrosino P, Marcuccio G, Raffio G, Formisano R, Candia C, Manzo F, et al.
Life (Basel)
. 2024 Jul;
14(7).
PMID: 39063652
Over the past 15 years, the paradigm of viewing the upper and lower airways as a unified system has progressively shifted the approach to chronic respiratory diseases (CRDs). As the...
12.
Perrotta F, Gentileschi S, Scriffignano S, Terribili R, Bianchi E, Frediani B, et al.
J Rheumatol
. 2024 Jul;
51(10):985-990.
PMID: 39009395
Objective: The main aim of the study was to evaluate the performance of 2 proposed criteria for difficult-to-treat (D2T) psoriatic arthritis (PsA) in a group of patients and to evaluate...
13.
Scriffignano S, Perrotta F, Fatica M, Conigliaro P, Chimenti M, Lubrano E
Rheumatol Ther
. 2024 Jul;
11(5):1393-1402.
PMID: 39003339
Introduction: The Patient Acceptable Symptoms State (PASS) is a validated instrument that is used to assess whether a patient with psoriatic arthritis (PsA) accepts her/his disease status by asking them...
14.
Scriffignano S, Perrotta F, Lubrano E
Curr Rheumatol Rep
. 2024 Jun;
26(9):321-331.
PMID: 38900205
Purposeof Review: Male fertility is an emergent issue that should be considered in clinical practice, when dealing with chronic inflammatory diseases in young men. As it is known, the chronic...
15.
Lubrano E, Perrotta F
Nat Rev Rheumatol
. 2024 May;
20(7):397-398.
PMID: 38773345
No abstract available.
16.
Phoka A, van den Bemt B, Lubrano E, Singh I, Fernandez-Carballido C, Parow D, et al.
Rheumatol Ther
. 2024 Apr;
11(3):773-794.
PMID: 38662146
Introduction: Several barriers to optimal care in axial spondyloarthritis (axSpA) exist, which is detrimental to patient outcomes. The Rheumacensus programme aimed to identify how the standard of care (SoC) and...
17.
Lubrano E, Scriffignano S, Perrotta F
Rheumatol Ther
. 2024 Apr;
11(3):663-674.
PMID: 38592646
Introduction: The concept of severity in a multidomain disease such as psoriatic arthritis (PsA) is still not well defined. The aim of this study was to identify the clinical characteristics...
18.
Macaluso F, Caprioli F, Benedan L, Bezzio C, Caporali R, Cauli A, et al.
Autoimmun Rev
. 2024 Mar;
23(5):103533.
PMID: 38521214
Spondyloarthritis (SpA) is the most frequent extraintestinal manifestation in patients with inflammatory bowel diseases (IBD). When IBD and spondyloarthritis coexist, musculoskeletal and intestinal disease features should be considered when planning...
19.
Perrotta F, Scrivo R, DAngelo S, Scriffignano S, Delle Sedie A, Coates L, et al.
Rheumatol Ther
. 2024 Mar;
11(3):553-562.
PMID: 38446398
Introduction: An overarching principle for the management of psoriatic arthritis (PsA) is a shared decision-making process between physicians and patients. The aim of this study is to assess the patient-physician...
20.
Riccieri V, Pellegrino G, Cipolletta E, Giuggioli D, Bajocchi G, Bellando-Randone S, et al.
J Scleroderma Relat Disord
. 2024 Feb;
9(1):38-49.
PMID: 38333531
Background: Intravenous iloprost has been widely used for the treatment of systemic sclerosis peripheral vasculopathy. No agreement has been found on the regimen and the dosage of intravenous iloprost in...